Find Derazantinib manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

API Suppliers

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

NDC API

NDC API

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

API

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

FDF Dossiers

0

FDA Orange Book

FDA (Orange Book)

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 1234356-69-4, Arq-087, Arq087, Derazantinib [usan], Arq 087, N9b0h171mj
Molecular Formula
C29H29FN4O
Molecular Weight
468.6  g/mol
InChI Key
KPJDVVCDVBFRMU-AREMUKBSSA-N
FDA UNII
N9B0H171MJ

Derazantinib
Derazantinib is an orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) with potential antineoplastic activity. Derazantinib binds to and potently inhibits the activity of FGFR subtypes 1, 2 and 3. This may result in the inhibition of FGFR-mediated signal transduction pathways, tumor cell proliferation, tumor angiogenesis and tumor cell death in FGFR-overexpressing tumor cells. FGFR, a receptor tyrosine kinase, is upregulated in many tumor cell types and plays a key role in tumor cellular proliferation, differentiation, angiogenesis and survival.
1 2D Structure

Derazantinib

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(6R)-6-(2-fluorophenyl)-N-[3-[2-(2-methoxyethylamino)ethyl]phenyl]-5,6-dihydrobenzo[h]quinazolin-2-amine
2.1.2 InChI
InChI=1S/C29H29FN4O/c1-35-16-15-31-14-13-20-7-6-8-22(17-20)33-29-32-19-21-18-26(24-10-4-5-12-27(24)30)23-9-2-3-11-25(23)28(21)34-29/h2-12,17,19,26,31H,13-16,18H2,1H3,(H,32,33,34)/t26-/m1/s1
2.1.3 InChI Key
KPJDVVCDVBFRMU-AREMUKBSSA-N
2.1.4 Canonical SMILES
COCCNCCC1=CC(=CC=C1)NC2=NC=C3CC(C4=CC=CC=C4C3=N2)C5=CC=CC=C5F
2.1.5 Isomeric SMILES
COCCNCCC1=CC(=CC=C1)NC2=NC=C3C[C@H](C4=CC=CC=C4C3=N2)C5=CC=CC=C5F
2.2 Other Identifiers
2.2.1 UNII
N9B0H171MJ
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 6-(2-fluorophenyl)-n-(3-(2-((2-methoxyethyl)amino)ethyl)phenyl)-5,6-dihydrobenzo(h)quinazolin-2-amine

2. Arq 087

2.3.2 Depositor-Supplied Synonyms

1. 1234356-69-4

2. Arq-087

3. Arq087

4. Derazantinib [usan]

5. Arq 087

6. N9b0h171mj

7. (6r)-6-(2-fluorophenyl)-n-(3-{2-[(2-methoxyethyl)amino]ethyl}phenyl)-5,6-dihydrobenzo[h]quinazolin-2-amine

8. Benzo(h)quinazolin-2-amine, 6-(2-fluorophenyl)-5,6-dihydro-n-(3-(2-((2-methoxyethyl)amino)ethyl)phenyl)-, (6r)-

9. Benzo[h]quinazolin-2-amine, 6-(2-fluorophenyl)-5,6-dihydro-n-[3-[2-[(2-methoxyethyl)amino]ethyl]phenyl]-, (6r)-

10. Derazantinib(arq-087)

11. Derazantinib [inn]

12. Derazantinib (arq 087)

13. Unii-n9b0h171mj

14. Derazantinib [who-dd]

15. Gtpl9785

16. Chembl4297187

17. Schembl13273847

18. Arq-087arq-087

19. Amy16754

20. Bcp29103

21. Ex-a1717

22. S8609

23. Who 10488

24. Akos037648596

25. Cs-7922

26. Db14889

27. Ac-30343

28. Bs-14785

29. Hy-19981

30. A16825

31. C71924

32. (6r)-6-(2-fluorophenyl)-5,6-dihydro-n-[3-[2-[(2-methoxyethyl)amino]ethyl]phenyl]-benzo[h]quinazolin-2-amine

33. (r)-6-(2-fluorophenyl)-n-(3-(2-((2-methoxyethyl)amino)ethyl)phenyl)-5,6-dihydrobenzo[h]quinazolin-2-amine

34. 1814961-15-3

2.4 Create Date
2010-08-02
3 Chemical and Physical Properties
Molecular Weight 468.6 g/mol
Molecular Formula C29H29FN4O
XLogP35.3
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count6
Rotatable Bond Count9
Exact Mass468.23253972 g/mol
Monoisotopic Mass468.23253972 g/mol
Topological Polar Surface Area59.1 Ų
Heavy Atom Count35
Formal Charge0
Complexity638
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty